TP53 and endometrial cancer: Of 116 high-risk endometrial cancer specimens analyzed by the TransPORTEC group, p53-abnormal (n=36) and NSMP (n=44) subgroups had significantly higher rates of distant metastases and lower 5-year relapse free survival than MSI-high (n=19) and POLE-mutant (n=14) tumours (48) (Table 4).